breast cancer - triple negative | ||
mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | |
anti-PD-(L)1 | ||
atezolizumab based treatment | ||
atezolizumab plus nab-paclitaxel | IMpassion-130 ... | IMpassion-130 ... |
atezolizumab plus paclitaxel | ||
pembrolizumab based treatment | ||
pembrolizumab plus SoC | KEYNOTE-355 ... | KEYNOTE-355 ... KEYNOTE-355 ... |